CIC
GSK icon

Crawford Investment Counsel’s GSK GSK Stock Holding History

Crawford Investment Counsel’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.1M Sell
636,839
-25,178
-4% -$1.36M 0.6% 51
2025
Q4 		$32.5M Sell
662,017
-29,243
-4% -$1.36M 0.54% 50
2025
Q3 		$29.8M Buy
691,260
+30,572
+5% +$1.19M 0.49% 54
2025
Q2 		$25.4M Buy
660,688
+359,803
+120% +$13.7M 0.44% 56
2025
Q1 		$11.7M Buy
+300,885
New +$11M 0.21% 97
2022
Q2 		– Sell
-426,474
Closed -$23.2M – 279
2022
Q1 		$23.2M Buy
426,474
+37,792
+10% +$2.05M 0.45% 55
2021
Q4 		$21.4M Buy
388,682
+4,191
+1% +$218K 0.41% 58
2021
Q3 		$18.4M Buy
384,491
+17,371
+5% +$873K 0.38% 59
2021
Q2 		$18.3M Buy
367,120
+14,807
+4% +$711K 0.37% 60
2021
Q1 		$15.7M Sell
352,313
-8,717
-2% -$396K 0.35% 66
2020
Q4 		$16.6M Buy
361,030
+4,305
+1% +$198K 0.41% 59
2020
Q3 		$16.8M Sell
356,725
-34,550
-9% -$1.73M 0.46% 52
2020
Q2 		$19.9M Buy
391,275
+4,053
+1% +$208K 0.57% 45
2020
Q1 		$18.3M Sell
387,222
-241,804
-38% -$12.9M 0.62% 45
2019
Q4 		$36.9M Buy
629,026
+10,810
+2% +$601K 0.96% 39
2019
Q3 		$33M Buy
618,216
+15,939
+3% +$820K 0.91% 40
2019
Q2 		$30.1M Buy
602,277
+4,083
+0.7% +$205K 0.85% 41
2019
Q1 		$31.2M Buy
598,194
+10,947
+2% +$547K 0.93% 39
2018
Q4 		$28M Buy
587,247
+112,085
+24% +$5.52M 0.95% 40
2018
Q3 		$23.9M Buy
475,162
+1,436
+0.3% +$73K 0.73% 42
2018
Q2 		$23.9M Sell
473,726
-2,706
-0.6% -$136K 0.76% 41
2018
Q1 		$23.3M Buy
476,432
+64,792
+16% +$3.02M 0.73% 43
2017
Q4 		$18.3M Sell
411,640
-32,470
-7% -$1.5M 0.57% 49
2017
Q3 		$22.5M Sell
444,110
-118,012
-21% -$5.99M 0.73% 43
2017
Q2 		$30.3M Buy
562,122
+60,564
+12% +$3.23M 1.04% 36
2017
Q1 		$26.4M Buy
501,558
+31,472
+7% +$1.6M 0.94% 38
2016
Q4 		$22.6M Buy
470,086
+29,780
+7% +$1.47M 0.82% 39
2016
Q3 		$23.7M Buy
440,306
+77,630
+21% +$4.26M 0.87% 38
2016
Q2 		$19.6M Buy
362,676
+25,372
+8% +$1.34M 0.78% 39
2016
Q1 		$17.1M Buy
337,304
+28,821
+9% +$1.44M 0.72% 39
2015
Q4 		$15.6M Buy
308,483
+25,390
+9% +$1.29M 0.69% 40
2015
Q3 		$13.6M Buy
283,093
+19,484
+7% +$1.01M 0.59% 37
2015
Q2 		$13.7M Buy
263,609
+176,996
+204% +$9.97M 0.52% 37
2015
Q1 		$5M Buy
86,613
+8,536
+11% +$489K 0.18% 71
2014
Q4 		$4.17M Buy
78,077
+2,791
+4% +$156K 0.15% 77
2014
Q3 		$4.33M Buy
75,286
+69,446
+1,189% +$4.26M 0.16% 73
2014
Q2 		$390K Hold
5,840
– – 0.01% 194
2014
Q1 		$390K Sell
5,840
-358
-6% -$24.2K 0.01% 192
2013
Q4 		$414K Hold
6,198
– – 0.02% 193
2013
Q3 		$389K Hold
6,198
– – 0.02% 186
2013
Q2 		$387K Buy
+6,198
New +$393K 0.02% 166

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Crawford Investment Counsel's GSK Position: Q1 2026 in Review

Crawford Investment Counsel reduced its GSK (GSK) stake by 3.8% in Q1 2026, selling an estimated $1.36M and leaving 636,839 shares worth $35.1M. The position accounts for 0.6% of the portfolio, ranked #51.

Crawford Investment Counsel first reported a position in GSK in Q2 2013 and has held it in 41 quarters since. The position peaked at $36.9M in Q4 2019. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Crawford Investment Counsel held 636,839 shares of GSK worth $35.1M as of Q1 2026.
  • Crawford Investment Counsel sold 25,178 GSK shares in Q1 2026, an estimated $1.36M.
  • GSK made up 0.6% of Crawford Investment Counsel's portfolio in Q1 2026, its #51 holding.
  • Crawford Investment Counsel first reported a position in GSK in Q2 2013 and has held it in 41 quarters since.
  • Crawford Investment Counsel's GSK position peaked at $36.9M in Q4 2019.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Crawford Investment Counsel's 13F filing for Q1 2026, filed 15 May 2026.